The Physiological Role of Lipoprotein (a).
Lipoprotein (a) (Lp(a)) is one of the most atherogenic lipoproteins, and, although we know plenty about the pathophysiology of Lp(a), its physiological function and metabolism remain elusive. From our previous results and more recent reports, the following model of Lp(a) metabolism emerges: apolipoprotein a (apo(a)) is biosynthesized in liver cells and the size of the isoform determines its rate of synthesis and excretion. In a first step, specific kringle IV domains in apo(a), mainly T-6 and T-7, bind to circulating low-density lipoproteins, followed by a second step in which stabilization of the newly formed Lp(a) complex is achieved by a disulfide bridge. Circulating Lp(a) interacts specifically with kidney cells, or possibly other tissues, causing cleavage of 2/3­3/4 of the N-terminal part of apo(a) by a collagenase-type protease. Part of these apo(a) fragments are found as excretory products of Lp(a) in urine, but there are indications that they, in fact, represent the biologically active form of apo(a) and are possibly responsible for the atherogenicity of Lp(a). Strategies for reducing this atherogenic lipoprotein with medication should, therefore, aim at interfering with either the assembly of Lp(a) or the stimulation of apo(a) fragmentation. (c) 2002 Prous Science. All rights reserved.
Kostner
Karam M.
KM
Kostner
Gert M.
GM